Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 3/20 | 0.60 |
| ▸ | BRAF | P15056 | 2/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16735356 | 0.83 | RAF1 (0.84) | RAF1BRAFMAPK14TRPV1KDR | |
| SCHEMBL16735355 | 0.81 | RAF1 (0.66) | RAF1BRAFMAPK14TRPV1KDR | |
| SCHEMBL16735227 | 0.80 | BRAF (0.73) | RAF1BRAFMAPK14KDR | |
| SCHEMBL13459592 | 0.79 | RIPK1 (0.69) | TRPV1KDRFLT1 | |
| SCHEMBL19376853 | 0.78 | KDR (0.55) | RAF1BRAFMAPK14TRPV1KDR | |
| SCHEMBL16735269 | 0.75 | RAF1 (1.00) | RAF1BRAFKDR | |
| SCHEMBL2679751 | 0.74 | NAMPT (0.64) | BRAFMAPK14TRPV1KDR | |
| SCHEMBL10054909 | 0.74 | NAMPT (0.64) | BRAFMAPK14TRPV1KDR | |
| SCHEMBL2679749 | 0.74 | NAMPT (0.64) | BRAFMAPK14TRPV1KDR | |
| SCHEMBL4548992 | 0.73 | KDR (0.72) | RAF1BRAFMAPK14KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388165-B2 | Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2016-07-12 | — | — | US | disclosed |
| US-20150191450-A1 | ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191450-A1 | ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | CSNK1A1, MAP3K5, MAP4K2 | RAF1 96/4885BRAF 204/4885MAPK14 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.